Broncus Holding Corporation (2216.HK)

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); RF-II, transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Ablation System for the treatment of COPD; H-Marker, treatment for lung cancer/lung nodules; disposable nebulizing micro-catheter for endoscope used for accurate anti-inflammation, local hemostasis, phlegm reduction and elimination, staining location, and local anesthesia; and BroncTru, a disposable transbronchoscopic puncture dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPoint ATV System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and BioStarNeedle, ATV FleXNeedle CN, ATV Sheath, ATV Balloon, and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China. Show more